Prostate Specific Antigen Level and Gleason Score in Indonesian Prostate Cancer Patients

Muhammad Imam Al Kautsar Herawan, Ricky Adriansjah

Abstract


In Indonesia, the number of prostate cancer continues to increase and even becomes the most common malignancy in men in 2015. Delayed early detection of prostate cancer is a significant concern. Prostate-specific antigen (PSA) level is found to be elevated in various conditions of prostate tissue damage, including prostate cancer. The extent of tissue damage in prostate cancer, represented by the Gleason score, is suspected to be related to the increase in the PSA level in the bloodstream. To investigate the relationship between the PSA level and Gleason scores in prostate cancer patients, a cross-sectional observational study was conducted. The study population consisted of 83 prostate cancer patients treated in Dr. Hasan Sadikin General Hospital Bandung, Indonesia, from 2017 to 2021. Data collected were analyzed using Spearman correlation test was used with an alpha value of 5%. Results indicated that 37.3% patients had a PSA level above 200 ng/dL, and 25.3% had a PSA level between 10-50 ng/dL. The majority of patients (48.1%) had a Gleason score of 9-10 (ISUP 5), while 24.1% had a score of 8 (ISUP 4). Bivariate analysis showed no significant relationship between the PSA level and Gleason score (p-value=0.445). Further studies are needed to determine the sensitivity and specificity of PSA in diagnosing prostate cancer.

Keywords


Gleason grading, prostate cancer, prostate-specific antigen

Full Text:

PDF

References


  1. WHO. Cancer 2022. [Internet] 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
  2. American Cancer Society. Key statistics for prostate cancer: Prostate cancer facts. [Internet] 2023 [cited 2023 Mei 25]. Available from: https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660
  4. Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2013;22(1):4–11. doi:10.1159/000338393
  5. Safriadi F, Novesar AR. Five-Year profiles of prostate cancer patients in a tertiary Hospital in Indonesia. MKB. 2021;53(2): 101–6. doi:10.15395/mkb.v53n2.2212
  6. Umbas R. Panduan penatalaksanaan kanker prostat. Jakarta: Ikatan Ahli Urologi Indonesia; 2022.
  7. Laccetti AL, Morris MJ, Kantoff PW. A Clinical evaluation of enzalutamide in metastatic castration-sensitive prostate cancer: guiding principles for treatment selection and perspectives on research. Onco Targets Ther. 2020;13:13247–63. doi:10.2147/OTT.S242921
  8. Albertsen PC. Prostate cancer screening with prostate-specific antigen: Where are we going?. Cancer. 2018;124(3):453–55. doi:10.1002/cncr.31140
  9. Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N'Dow J, Sønksen J, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur Urol. 2021;80(6):703–11. doi:10.1016/j.eururo.2021.07.024
  10. Chen N, Zhou Q. The evolving Gleason grading system. Chin J Cancer Res. 2016;28(1):58–64. doi:10.3978/j.issn.1000-9604.2016.02.04
  11. Fang Y, Zhou X, Qiu J, Wen X, Wang D, Pang J, et al. Serum PSA level and gleason scores of needle biopsy specimens predict the postoperative pathologic grade of prostate cancer. Acta Medica Mediterr. 2013;29(2):279–83.
  12. Amarneel S, Gohil MR, Parmar KN, Gamit S, Vala M, Shukla D. Study of serum prostate specific antigen level in prostate biopsy specimens. International Journal of Innovative Research and Development. [Internet] 2015 [cited 2023 Mei 15]. Available from: http://www.ijird_ojs/article/view/135677/0.
  13. Jayapradeep D, Prakash V, Philose T, Pai M. Histomorphologic Ccorrelation of PSA levels in prostatic pathology. Natl J Lab Med. 2017;6(4):28–32. https://doi.org/10.7860/NJLM/2017/30113:2262
  14. Gurumurthy D. Prostate carcinoma: correlation of histopathology with serum prostate specific antigen. Science Journal of Clinical Medicine 2015;4:1. https://doi.org/10.11648/j.sjcm.s.2015040401.11.
  15. Bhowmick NA, Oft J, Dorff T, Pal S, Agarwal N, Figlin RA, et al. COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocr Relat Cancer. 2020;27(9):R281–92. doi:10.1530/ERC-20-0165
  16. Jairath NK, Dal Pra A, Vince R, Dess RT, Jackson WC, Tosoian JJ, et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol. 2021;79(3):374–83. https://doi.org/10.1016/j.eururo.2020.11.021.
  17. Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2014;1846:99–112. https://doi.org/10.1016/j.bbcan.2014.04.001.
  18. Das J, Paul AK, Haque N, Dan KK, Saha S, Khan TI, et al. Correlation of prostate specific antigen, gleason score and bone metastases in bone scan in prostate cancer patient. SAS J Med. 2021;7(3):85–9. https://doi.org/10.36347/sasjm.2021.v07i03.005.




DOI: https://doi.org/10.15395/mkb.v56.3571

Article Metrics

Abstract view : 223 times
PDF - 83 times

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


 


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats